Publicaciones en colaboración con investigadores/as de University of Copenhagen (6)

2020

  1. Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

    Diabetes, Obesity and Metabolism, Vol. 22, Núm. 8, pp. 1339-1347

2019

  1. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: A post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

    Cardiovascular Diabetology, Vol. 18, Núm. 1

  2. Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

    Diabetes, Obesity and Metabolism, Vol. 21, Núm. 6, pp. 1506-1512

2018

  1. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)

    Calcified Tissue International, Vol. 103, Núm. 4, pp. 359-371

2016

  1. Fracture rate, back pain and quality of life in patients with osteoporosis treated with teriparatide: Results of the European observational study ExFOS (Extended Forsteo® Observational Study)

    Revue du Rhumatisme (Edition Francaise), Vol. 83, pp. A188-A189

  2. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

    New England Journal of Medicine, Vol. 375, Núm. 19, pp. 1834-1844